Novel Agents for the Treatment of Pancreatic Adenocarcinoma: Any Light at the End of the Tunnel?
Abstract
Pancreatic cancer is a disease with dismal prognosis and treatment options are limited. Development of novel active compounds is mandatory. A number of pancreatic cancer clinical trials that included a novel agent among their arms were presented at the recent 2010 American Society of Clinical Oncology (ASCO) Annual Meeting. It appears that IGF-1R inhibition might be effective and this should be tested in further trials. Microtubule stabilization with ixabepilone in combination with EGFR does not lead to promising improvement in prognosis whereas nab-paclitaxel in combination with anti-angiogenetic agents is a combination not previously tested that showed an acceptable safety profile. This combination might be worth testing in a phase II clinical trial. Last but not least, CTLA-4 blockade has an acceptable toxicity profile but its efficacy needs to be proven over placebo in phase II and III trials. Finally, understanding of the tumor biology and biomarker analysis from the clinical trials is warranted.
Image: Yale University School of Medicine. New Haven, CT, USA.
Downloads
References
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009; 59:225-49. [PMID 19474385]
Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362:1605-17. [PMID 20427809]
Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010; 16:2505-11. [PMID 20388847]
Kindler HL, Richards DA, Stephenson J, Garbo LE, Rocha Lima CS, Safran H, et al. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol 2010; 28(15 Suppl):4035.
Javle MM, Varadhachary GR, Shroff RT, Bhosale B, Overman BM, Weatherly J, et al. Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4039.
Rocha Lima CS, Lin EH, Kim GP, Giguere JK, Marshall J, Zalupski M, et al. Phase II trial of ixabepilone (IXA) plus cetuximab (C) as first-line therapy for advanced pancreatic carcinoma (PC). J Clin Oncol 2010; 28(15 Suppl):4086.
El-Khoueiry AB, Iqbal S, Lenz H, Roman L, Gitlitz BJ, Yang D, et al. A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28(15 Suppl):3059.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 Jun 5. [PMID 20525992]
M. Aglietta M, C. Barone C, M. Muliello, C. Bagalà, D. Ferraro, K. D. Fly, et al. A phase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy-naive metastatic pancreatic cancer. J Clin Oncol 2010; 28(15 Suppl):4134.
Van Cutsem E, Vervenne W, Bennouna J Humblet Y, Gill S, Van Laethem J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231-7. [PMID 19307500]
Copyright (c) 2010 Anastasios T Dimou, Konstantinos N Syrigos, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.